Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire and New River to co-market late-stage ADHD drug
Under the terms of the agreement, the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the US. Shire will book the product sales and New
Under the terms of the agreement, the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the US. Shire will book the product sales and New
Electronic applications for the rotigotine patch were submitted to both the FDA and the European Medicines Evaluation Agency (EMEA) on September 29, 2004. While the application form was
TREE-2 is the first study to assess the safety of Eloxatin-based regimens combined with Genentech’s Avastin (bevacizumab) for the first-line treatment of metastatic colorectal cancer. Preliminary efficacy results
The two companies will form a joint development team to oversee the development of tesmilifene in gastric cancer. Shin Poong will fully fund development costs and provide an
The FDA accepted Voyager’s investigational new drug application (IND) and clinical protocol in late December 2004. This unique formulation is being used in the present study in healthy
The multiple sclerosis interferon enhancing therapy (MS-IET) combines interferon-b with Transition’s enhancing agent, EMZ701, with the goal of improving outcomes in multiple sclerosis patients without adding toxicity. The
The Joslin study is a major milestone in understanding why being overweight can lead to a host of health problems, including type 2 diabetes and heart disease. Researchers
In August 2003, a US District Court held Merck’s US patent for once-weekly administration of Fosamax (alendronate sodium) to be valid and infringed by Teva Pharmaceuticals’ abbreviated new
A priority designation can be given to an new drug application (NDA) for Tygacil that, if approved, would be a significant improvement compared with existing treatments. Tygacil is
The fast-track designation will provide for expedited regulatory review for Viprinex (ancrod), which is under development for decreasing disability in patients with acute non-hemorrhagic stroke, treated within six